Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Blood (2025) 146 (Supplement 1): 7229.

https://doi.org/10.1182/blood-2025-7229

Published: 2025

Journal Articles

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Peipei Ye, Renzhi Pei, Lihong Shou, Jie Jin, Hongyan Tong, Huifang Jiang, Linlong Xu, Jian Shen, Sai Chen, Gongqiang Wu, Dong Chen, Shuangyue Li, Jingcheng Zhang, Huang Li, Fujiang Song, Weiying Feng, Chao Hu, Ying Lu

Blood (2025) 146 (Supplement 1): 5960.

https://doi.org/10.1182/blood-2025-5960

Published: 2025

Journal Articles

Adult hemophagocytic lymphohistiocytosis: A multicenter retrospective analysis of etiology and impact on survival in China

Jingsong He, Lixia Zhu, Mengqi Xiong, Jianguo Zhang, Yinyi Zhang, Xin Guo, Linjie Li, Lihong Shou, Qunyi Guo, Shuangwei Ying, Li Li, YI LI, Zhen Cai, He Huang, Xiu-Jin Ye

Blood (2025) 146 (Supplement 1): 6549.

https://doi.org/10.1182/blood-2025-6549

Published: 2025

Journal Articles

Prognostic significance of 1q21 gain/amplification and co-existing cytogenetic abnormalities in Chinese patients with newly diagnosed multiple myeloma

Xinyuan Dai, YI LI, Gaofeng Zheng, Xiaoyan Han, Minlei Zhao, Yang Yang, Donghua He, Li Yang, Dan Cao, Lihong Shou, Linjie Li, Haowen Xiao, Wenjun Wu, Yi Zhao, Zhen Cai, Jingsong He

Blood (2025) 146 (Supplement 1): 2242.

https://doi.org/10.1182/blood-2025-2242

Published: 2025

Journal Articles

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1907.

https://doi.org/10.1182/blood-2025-1907

Published: 2025

Journal Articles

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

Jian Huang, Rumeng Li, Tiejun Gong, Pengxiang Guo, Lihong Shou, Hu Zhu, Zongjiu Jiao, Feng Zhang, Qingchi Liu, Lidong Zhao, Guocai Wu, Lili Chen, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 5530.

https://doi.org/10.1182/blood-2025-5530

Published: 2025

Journal Articles

Real-world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia

Nianci Chen, Yu Zhu, Zhenqi Huang, Ying Lu, Yinjun Lou, Liping Mao, Xinping Zhou, Dan Chen, Lihong Shou, Huang Li, Cuihua Fan, Hongyan Tong, Jie Jin, Huafeng Wang, East China Leukemia Alliance (Ecla)

Blood (2025) 146 (Supplement 1): 5237.

https://doi.org/10.1182/blood-2025-5237

Published: 2025

Journal Articles

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Qingchi Liu, Lihong Shou, Feng Zhang, Cuicui Wu, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 7351.

https://doi.org/10.1182/blood-2025-7351

Published: 2025

Journal Articles

Etoposide-cytarabine-pegfilgrastim (EAP) and disease-specific chemotherapy regimens for hematopoietic stem cell mobilization in lymphoma: A randomized phase III trial

Peipei Ye, Renzhi Pei, Jie Jin, Hongyan Tong, Lihong Shou, Huifang Jiang, Jingcheng Zhang, Sai Chen, Linlong Xu, Yanping Shao, Dong Chen, Shuangyue Li, Huang Li, Jing le, Yangxi Jin, Chao Hu, Ying Lu

Blood (2025) 146 (Supplement 1): 4182.

https://doi.org/10.1182/blood-2025-4182

Published: 2025

Journal Articles

A prospective, multicenter study on stem cell mobilization using EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma

Blood (2025) 146 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2025-4179

Published: 2025

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Blood (2024) 144 (Supplement 1): 836.

https://doi.org/10.1182/blood-2024-208355

Published: 2024

Journal Articles

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Lihong Shou, Qingchi Liu, Feng Zhang, Cuicui WU, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2024) 144 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2024-210330

Published: 2024

Journal Articles

Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial

Blood (2024) 144 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2024-201872

Published: 2024

Journal Articles

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2024-200064

Published: 2024

Journal Articles

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

Hu Zhou, Xuewen Song, Zengmei Sheng, Feng Zhang, Guocai Wu, Lidong Zhao, ZePing Zhou, Lihong Shou, Lili Chen, Xiaotao Wang, Jian Huang, Rong Fu, Dan Chen, Ruibin Huang, Zongjiu Jiao, Jian Lu, Yajun Ruan, Yu Jiao

Blood (2024) 144 (Supplement 1): 5406.

https://doi.org/10.1182/blood-2024-200074

Published: 2024

Journal Articles

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Lin Shen, Jing Bao, Lihong Shou, Ying Lu, Qi Zhu, Li Wang, Weili Zhao

Blood (2024) 144 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2024-204547

Published: 2024

Journal Articles

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Nianci Chen, Jiajia Pan, Yile Zhou, Liping Mao, Yinjun Lou, Jiejing Qian, Gaixiang Xu, Juying Wei, De Zhou, Lihong Shou, Huang Li, Minchao Yan, Hui Zeng, Cuihua Fan, Gongqiang Wu, Weiying Feng, Hongyan Tong, Jie Jin, Huafeng Wang

Blood (2023) 142 (Supplement 1): 5926.

https://doi.org/10.1182/blood-2023-182806

Published: 2023

Journal Articles

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Yi Li, Jingsong He, Xiaoyan Han, Gaofeng Zheng, Enfan Zhang, Qingxiao Chen, Donghua He, Yi Zhao, Jiaping Fu, Lihong Shou, Wenhua Jiang, Wei Jiang, Shenxian Qian, Huixian Hu, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2021-149188

Published: 2021

Journal Articles

Venetoclax-Ponatinib for T315I/Compound-Mutated Ph+Acute Lymphoblastic Leukemia

Huafeng Wang, Jiejing Qian, Chang Yang, Yi Zhang, Yungui Wang, Ting Shi, Yongxian HU, Liping Mao, Xiujin Ye, Fang Liu, Zhenfang Xi, Lihong Shou, Caiyun Fu, Hua Naranmandura, Jie Jin, Hong-Hu Zhu

Blood (2021) 138 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2021-152836

Published: 2021

Journal Articles

The Effect of Dipeptiven in Patients after Allogenic Hematologic Stem Cell Transplantation.

He Huang, PhD, MD, Lihong Shou, MD, Yi Luo, MD, Jimin Shi, MD, Xiaoli Zhu, MD, Zhen Cai, PhD, MD, Maofang Lin, MD

Blood (2005) 106 (11): 5371.

https://doi.org/10.1182/blood.V106.11.5371.5371

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Adult hemophagocytic lymphohistiocytosis: A multicenter retrospective analysis of etiology and impact on survival in China

Prognostic significance of 1q21 gain/amplification and co-existing cytogenetic abnormalities in Chinese patients with newly diagnosed multiple myeloma

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

Real-world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Etoposide-cytarabine-pegfilgrastim (EAP) and disease-specific chemotherapy regimens for hematopoietic stem cell mobilization in lymphoma: A randomized phase III trial

A prospective, multicenter study on stem cell mobilization using EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Venetoclax-Ponatinib for T315I/Compound-Mutated Ph+Acute Lymphoblastic Leukemia

The Effect of Dipeptiven in Patients after Allogenic Hematologic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only